Probiotics for standard triple helicobacter pylori eradication: A randomized, double-blind, placebo-controlled trial

Medicine (United States)

Volumn 94, Issue 17, 2015, Pages e685-

  Hauser, Goran ^a   Salkic, Nermin ^b   Vukelic, Karina ^a   JajacKnez, Alenka ^a   Stimac, Davor ^a  

^a KBC RIJEKA   (Croatia)

^b University Clinical Centre   (Bosnia and Herzegovina)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADJUVANT THERAPY; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BIFIDOBACTERIUM; BLOATING; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIGASTRIC PAIN; FLATULENCE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LACTOBACILLUS RHAMNOSUS; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; TASTE DISORDER; VOMITING; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HELICOBACTER INFECTIONS; MALE; MIDDLE AGED; QUESTIONNAIRE; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZITHROMYCIN; BIFIDOBACTERIUM; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOBACILLUS RHAMNOSUS; LANSOPRAZOLE; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PLACEBOS; PROBIOTICS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84937512467     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000685     Document Type: Article

References (42)

1. Metchnikoff E. The prolongation of life. Optimistic studies. New York: Putman's Sons; 1908:161-183.
2. Marteau PR, de Vrese M, Cellier CJ, et al. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001;73:430S-436S.
3. Gotz V, Romankiewicz JA, Moss J, et al. Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm. 1979;36:754-757.
4. Borgia M, Sepe N, Brancato V, et al. A controlled clinical study on Streptococcus faecium preparation for the prevention of side reactions during long-term antibiotic treatments. Curr Ther Res. 1982;31:265-271.
5. Clements ML, Levine MM, Ristiano PA, et al. Exogenous lactobacilli fed to man. Their fate and ability to prevent diarrheal disease. Prog Food Nutr Sci. 1983;7:29-37.
6. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989;96:981-988.
7. Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Ann Med. 1990;22:57-59.
8. Colombel JF, Cortot A, Neut C, et al. Yoghurt with Bifidobacteriumlongum reduces erythromcyin-induced gastrointestinal effects. Lancet. 1987;2:43.
9. Hilton E, Kolakowski P, Singer C, et al. Efficacy of Lactobacillus GG as a diarrheal preventive in travellers. J Travel Med. 1997;4: 41-43.
10. Kollaritsch H, Stemberger H, Ambrosch P, et al. Prophylaxe des ReisendiarrhoemiteinemLyophilisat von Lactobacillus acidophilus. (Prophylaxis of travellers' diarrhea using a Lactobacillus acidophilus lyophilisate.) Garmisch-Partenkirchen, Germany: GemeinsameTagung des DeutschenTropenmedizinischenGesellschaft und der Ö sterreichischenGesellschaft fur Tropenmedizin und Parasitologie, 1983:Abstract 92.
11. Black FT, Andersen PL, Orskov J, et al. Prophylactic efficacy of lactobacilli on traveller' sdiarrhea. Travel Med. 1989;7:333-335.
12. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of traveller's diarrhea by Lactobacillus GG. Ann Med. 1990;22:53-56.
13. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30:54-60.
14. Guarino A, Canani RB, Spagnuolo MI, et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr. 1997;25:516-519.
15. Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992;32:141-144.
16. Isolauri E, Kaila M, Mykkanen H, et al. Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci. 1994;39:2595-2600.
17. Guarino A, Canani RB, Spagnuolo MI, et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr. 1997;25:516-519.
18. Buydens P, Debeuckelaere S. Efficacy of SF 68 in the treatment of acute diarrhea. A placebo-controlled trial. Scand J Gastroenterol. 1996;31:887-891.
19. Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res. 1989;17:333-338.
20. Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646-664.
21. Tonkic A, Tonkic M, Lehours P, et al. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter. 2012;17:1-8.
22. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol. 2004;4:26.
23. Hintze, J. (2009). PASS 11. NCSS, LLC. Kaysville, Utah, USA. www.ncss.com.
24. StatSoft, Inc. (2011). STATISTICA (data analysis software system), version 10. www.statsoft.com.
25. Venerito M, Krieger T, Ecker T, et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88:33-45.
26. Padilla Ruiz M, FernańdezAguiar ME, Arce Nunẽz M, et al. Lactobacillus rhamnosus GG supplementation to reduce side-effects of anti-Helicobacter pylori treatment. Rev Gastroenterol Peru. 2013;33:121-130.
27. Jonkers D, Stockbruegger R. Review article: Probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther. 2007;26: 133-148.
28. Patel A, Shah N, Prajapati JB. Clinical appliance of probiotics in the treatment of Helicobacter pylori infection: a brief review. J MicrobiolImmunol Infect. 2006;8:103-109doi: 10.1016/ j.jmii.2013.03.010.(Epub).
29. Pinchuk IV, Bressollier P, Verneuil B, et al. In vitro anti- Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother. 2001;45:3156-3161.
30. Medeiros JA, Pereira MI. The use of probiotics in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:1-5.
31. Franceschi F, Cazzato A, Nista EC, et al. Role of probiotics in patients with Helicobacter pylori infection. Helicobacter. 2007;12:59-63.
32. Aiba Y, Suzuki N, Kabir AM, et al. Lactic acid-mediated suppressionof Helicobacter pylori by the oral administration ofLactobacillussalivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol. 1998;93:2097-2101.
33. Navarro-Rodriguez T, Silva FM, Barbuti RC, et al. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreasesthe adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013;13:56.
34. Dajani AI, Abu Hammour AM, Yang DH, et al. Do probiotics improve eradication response to Helicobacter pylori onstandard triple or sequential therapy? Saudi J Gastroenterol. 2013;19:113-120.
35. Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25:155-168.
36. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069-1079.
37. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:25-32.
38. Plecko V, Katicic M, VardaBrkic D, et al. Primary resistance of Helicobacter pylori to macrolides and metronidazole in the northern part of Croatia. Helicobacter. 2012;17(Suppl. 1):107.
39. Glupczynski Y, Megraud F, Lopez-Brea M, et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20:820-823.
40. Molina-Infante J, Gisbert JP. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. Rev Esp Enferm Dig. 2013;105:441-444.
41. Zhou L, Zhang J, Chen M, et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol. 2014;109: 535-541.
42. Katicic M, Duvnjak M, Kanizaj TF, et al. Croatian guidelines for diagnostics and treatments of Helicobacter pylori infection. LijecVjesn. 2014;136:1-17.